This inventor holds 49 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Nucleic Acid Detection. Top assignees: Epoch Pharmaceuticals, Inc., Epoch Biosciences, Inc., Cepheid Corporation. Active years: 1997-2024.
Location History:
- Bothell, WA (US) (1997 - 2013)
- Woodinville, WA (US) (2004 - 2024)
Company Filing History:
15 out of 21 
13 out of 32 
9 out of 191 
Years Active: 1997-2024
Areas of Expertise:
Title: Igor V. Kutyavin: A Pioneer in Oligonucleotide Research
Introduction
Igor V. Kutyavin, based in Woodinville, WA, is a distinguished inventor with an impressive portfolio of 49 patents to his name. His groundbreaking work primarily focuses on the field of oligonucleotide applications and enzyme interactions, showcasing innovations that have significant implications in biochemical research and diagnostics.
Latest Patents
Kutyavin's latest patents are notable for their contributions to the activation of DNA polymerases. One of his patents describes methods and compositions for the inhibition of DNA polymerases by uracil-DNA glycosylase-cleavable oligonucleotide ligands. In this innovative approach, he provides methods for activating aptamer-deactivated DNA polymerases by modifying the aptamer, thus activating DNA synthesis activity in a reaction mixture. The methods can also be employed using kits that feature DNA polymerase-binding oligonucleotide aptamers alongside uracil-DNA glycosylase enzymatic activity.
Another significant patent involves the inhibition of nucleic acid polymerases by endonuclease V-cleavable circular oligonucleotide ligands. This invention details methods for activating DNA polymerases by cleaving the aptamer via endonuclease V enzymatic activity. This clever mechanism reduces the aptamer's binding to DNA polymerases, once again leading to the activation of DNA synthesis within a reaction mixture.
Career Highlights
Throughout his career, Kutyavin has made substantial contributions to the biopharmaceutical field. He has had significant stints at Epoch Pharmaceuticals, Inc. and Epoch Biosciences, Inc., where his expertise in oligonucleotide research has driven many of his notable inventions. His work in these companies has positioned them at the forefront of innovative nucleic acid research.
Collaborations
Kutyavin has collaborated with esteemed colleagues in the field, including Rich B Meyer, Jr. and Irina Aleksandrovna Afonina. Their combined expertise has led to advancements in their research efforts and has fostered an environment of innovation in their respective projects.
Conclusion
With a rich portfolio of patents and a career marked by significant achievements in the realm of oligonucleotides, Igor V. Kutyavin continues to be a pivotal figure in scientific research. His inventive methodologies not only advance our understanding of DNA polymerases but also pave the way for future innovations in genetic research and therapeutic applications.